Publicado en El Confidencial 27-11-2024
Published by EXPANSIÓN 2022-03-08
Oncomatryx has carried out a capital increase of 15 million euros to start clinical trials with people with invasive tumors in Spain and the USA.
Published by El Correo 2022-03-07. Oncomatryx Biopharma, S.L. has been honoured with the 2022 Bizkaia Social Impact Award (Premio Impacto Social 2022) by BBK and EL CORREO at the Sustainable Competitiveness Awards (Premios de Competitividad Sostenible).
Published by La Vanguardia 2015-12-15. Oncomatryx expands capital to complete the preclinical phase of drugs against tumor stroma The Basque company Oncomatryx has completed a round of capital increase of 4.5 million euros with the aim of completing the preclinical trials of the “pioneer” molecule named OMTX, which has been developed against the tumor stroma, … Leer más
Press Release 2013-06-26 DMTXinvascan tested in US hospitals. Hospitals in the USA launch a Basque test to predict the metastasis of breast cancer Current diagnostic systems impede the detection in time of 25% of expanded tumors A Spanish company develops a test that detects whether a breast cancer disease will develop metastasis Using this … Leer más
Publisehed by El Dato Magazine el 2013-01-01 New treatments against the most invasive cancer Develops in collaboration with renowned public and private national and foreign companies, new drugs that help to extend the patient’s life